Search the web
Welcome, Guest
[Sign Out, My Account]
Hoovers

Wednesday, February 10 2016 5:08pm ET - U.S. Markets Closed.
Industry Center - Biotechnology
Industry Center > Biotechnology > ESPERION THERAPEUTICS, INC. Company Profile
More On This Industry
· Summary
· News
· Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Biotechnology
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Conglomerates
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Need more? Get unbiased, in-depth information on public and private companies worldwide.
  
ESPERION THERAPEUTICS, INC. Company Profile
“Bad” cholesterol is public enemy #1 at Esperion Therapeutics. A biopharmaceutical company, Esperion researches and develops therapies that reduce elevated LDL-C levels in patients' blood. Its primary candidate, ETC-1002, has been under development since 2008 and is in clinical stage development. If the candidate is approved by the FDA, the company plans to market its drug to patients who are unable to physically tolerate widely used cholesterol drugs like statins. Esperion Therapeutics was formed in 2008 after former parent Pfizer spun the company's predecessor off. Esperion went public in 2013.
Headlines for ESPERION THERAPEUTICS, INC.
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Esperion Therapeutics, Inc. and a Lead Plaintiff Deadline of March 14, 2016
Business Wire - 2 hours, 54 minutes ago
ESPERION INVESTORS ALERT: Lieff Cabraser Reminds Investors of Deadline in Class Action Against Esperion Therapeutics, Inc.
Business Wire - Tue 5:09 pm ET
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Esperion Therapeutics, Inc. To Contact The Firm Before Upcoming Lead Plaintiff Deadline
PR Newswire - Tue 12:41 pm ET
INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Esperion Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm
Business Wire - Mon Feb 8
More Headlines...
More on ESPERION THERAPEUTICS, INC.
Quote Insider
News Financials
Profile    
Research    
Contact Information
Address: 3891 Ranchero Dr.,Ste. 150
Ann Arbor, MI 48108
Phone:734-887-3903
Fax:
Financial Highlights
Fiscal Year End:December
Revenue (2014):3.00 M
Employees (2014):21
Employee Growth (1 yr):23.50%
Key People
Executive Chairman, Chief Scientific Officer: Roger S. Newton
President, Chief Executive Officer and Director: Tim M. Mayleben
Chief Medical Officer: Noah L. Rosenberg
Industry Information
Sector: Healthcare
Industry: Biotechnology
Top Competitors
NOVARTIS PHARMACEUTICALS CORPORATION
Astrazeneca Pharmaceuticals LP
PFIZER INC. (pfe)
 


Copyright © 2016 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2016 Morningstar, Inc. All Rights Reserved. Company information © 2016 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2016, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?